CN107417772A - It is a kind of can antagonism hnRNPU protein rna binding activity polypeptide HIP 20 and its application - Google Patents
It is a kind of can antagonism hnRNPU protein rna binding activity polypeptide HIP 20 and its application Download PDFInfo
- Publication number
- CN107417772A CN107417772A CN201710802024.2A CN201710802024A CN107417772A CN 107417772 A CN107417772 A CN 107417772A CN 201710802024 A CN201710802024 A CN 201710802024A CN 107417772 A CN107417772 A CN 107417772A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- hnrnpu
- domain
- antineoplastic
- hip
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Abstract
The invention provides it is a kind of can antagonism hnRNPU protein rna binding activity polypeptide and its application, its amino acid sequence such as SEQ ID NO:Shown in 1；A kind of antineoplastic polypeptide and its application are further related to, the antineoplastic polypeptide includes tumor cytotoxicity domain and wears spanning domain, the amino acid sequence such as SEQ ID NO of tumor cytotoxicity domain:Shown in 1.The spanning domain of wearing of the antineoplastic polypeptide of the present invention does not have cytotoxicity in itself, but after connection tumor cytotoxicity domain, there is the obvious effect for suppressing tumor proliferation, migrating invasion and attack.The antineoplastic polypeptide of the present invention, it can not only be expected to combine other treatment mode to suppress tumour separately as antitumor biotherapeutics.
Description
Technical field
The present invention relates to neoplasm targeted therapy field, more specifically it relates to which one kind can the combination work of antagonism hnRNPU protein rnas
The polypeptide of property and its application.
Background technology
It is well known that tumour is worldwide difficult medical problem, greatly endangered to mankind's health care belt.Conventional is swollen
Often tissue specificity is poor for knurl medicine, and normal tissue brings damage while tumour is killed, and causes very big secondary work
With bringing great pain to tumor patient.Therefore, the research and development of specificity tumor-targeting polypeptide drugs high, evident in efficacy
Cause the great interest of people.
Cancer target polypeptide is a kind of active peptides for referring to the specific molecular that target tumor occurs, development is related, is
It is now recognized that optimal tumor-targeting treatment means.Relative to classic chemotherapy medicine, tumor-targeting polypeptide has following
Advantage：1. good penetration into tissue, easily play lethal effect into tumour cell；2. bioactivity is high, high specificity, exempt from
Epidemic focus is low and toxic reaction is relatively weak；3. plasma clearance speed is fast, accumulation is not likely to produce in vivo；4. with other drugs
Interact less, it is higher with the compatibility of internal target；5. it is easy to chemical synthesis.Therefore, many scholars make great efforts to seek in recent years
The small peptide of target tumor specific molecular is looked for, to reach the purpose of target tumor.
HnRNP (hnRNPs) is one group of rna binding protein, participates in tumour generation, virus infects, thin
A variety of pathophysiological processes such as born of the same parents' apoptosis.Wherein, hnRNPU is the maximum phosphorylating protein of molecular weight, transcription in gene,
Played a significant role in positioning and the expression particularly apparent inactivation of sex chromosome.HnRNPU is more to be answered with DNA/RNA albumen
Solvate form participates in cell function regulation, and its support land can strengthen the function of transcription factor, the transcription of controlling gene.
Increasing research confirms：The high expression in kinds of tumors of hnRNPU albumen, and by and the combination of internal non-coding RNA join
Invasion and attack with liver cancer, lung cancer are shifted.Although having there is the report of many new antitumoral polypeptides, which part has been enter into clinical examination
Test, still, report is there is no for the antineoplastic polypeptide of hnRNPU albumen.
Therefore, it is necessary to build one kind can targets neoplastic cells, and can efficiently enters the novel polypeptide of born of the same parents.
The content of the invention
To solve problem above, inventor have extensively studied the mechanism of action of hnRNPU albumen, it is found that hnRNPU passes through it
RGG domains be combined with each other so as to promote downstream oncogene or check suppression cancer with long-chain non-coding RNA (LOC101927219)
The transcription of gene.The interaction between hnRNPU albumen RGG domains and lncRNA is blocked, can effectively check tumour progression.
Based on the research, the invention provides it is a kind of can antagonism hnRNPU protein rna binding activity polypeptide, its amino acid
Sequence such as SEQ ID NO:Shown in 1.It is demonstrated experimentally that the polypeptide contestable antagonism promotion sensitivity gene hnRNPU and LncRNA knot
Close, and obvious tumor inhibition effect is shown in cellular level.
Present invention also offers it is above-mentioned can antagonism hnRNPU protein rna binding activity polypeptide in antineoplastic is prepared
Application.
Present invention also offers a kind of antineoplastic polypeptide, and it includes tumor cytotoxicity domain and wears spanning domain, institute
State the amino acid sequence such as SEQ ID NO of tumor cytotoxicity domain:Shown in 1.
Preferably, the amino acid sequence for wearing spanning domain such as SEQ ID NO:Shown in 2.
Preferably, the N-terminal worn spanning domain and be connected to the tumor cytotoxicity domain.
Present invention also offers application of the above-mentioned antineoplastic polypeptide in antineoplastic is prepared.
It is an advantage of the current invention that the spanning domain of wearing of the antineoplastic polypeptide of the present invention does not have cytotoxicity in itself, but even
After connecing hnRNPU RNA binding activity peptide fragments, obvious tumor inhibitory effect can be observed in cellular level.The present invention's is anti-swollen
Knurl polypeptide, it can not only be expected to combine other treatment mode to suppress tumour separately as antitumor biotherapeutics.
Brief description of the drawings
Fig. 1 is that control peptide and HIP-20 handle the fluorescent microscopy images of HeLa cells and SH-SY5Y cells after 48 hours；
Fig. 2 is to handle cell MTT colorimetric statistical charts with the HIP-20 or control peptide of various concentrations；
HIP-20 or control peptide that Fig. 3 is 20 μm of ol/L handle the MTT colorimetric statistical charts of cell different time；
Fig. 4 is soft-fractrue rock mass experiment photo；
Fig. 5 is the statistical chart according to Fig. 4 number of cell clones calculated；
Fig. 6 is Transwell cell invasion experiment photos；
Fig. 7 is the transport number purpose statistical chart according to Fig. 6 tumour cells calculated；
Fig. 8 is the angiogenic activity Inhibition test photo of tumour cell；
Fig. 9 is the relative angiogenic activity statistical chart of tumour cell；
Figure 10 is Peptide pull down experiment photos；
Figure 11 is RNA co-immunoprecipitation experiments (RIP) photo.
Embodiment
The principle and feature of the present invention are described below in conjunction with example, the given examples are served only to explain the present invention, and
It is non-to be used to limit the scope of the present invention.
1. the synthesis of antineoplastic polypeptide
A kind of antineoplastic polypeptide is synthesized by solid-phase synthesis, it includes a tumor cytotoxicity domain and one is worn
Spanning domain, wherein tumor cytotoxicity domain sequence such as SEQ ID NO:Shown in 1, spanning domain sequence such as SEQ ID are worn
NO:Shown in 2, the N-terminal of tumor cytotoxicity domain is connected to, resulting sequence is：Amino acid sequence is
YGRKKRRQRRR-NMRGGNFRGGAPGNRGGYNK(SEQ ID NO:3), it is named as HIP-20.In order to study conveniently, we
In the C-terminal connection marked by fluorescein isothiocyanate FITC of antineoplastic polypeptide.
Synthesis is carried out from C-terminal to N-terminal, and step is as follows：
A. n equivalent resins are weighed and are put into reactor, DCM (dichloromethane) swelling half an hour is added, then takes out DCM, add
Enter first amino acid 2n equivalent in sequence, add DIEA (diisopropylethylamine), appropriate DMF (the dimethyl formyls of 2n equivalents
Amine), DCM (referring to be advisable so that resin can be made fully to agitate in right amount), nitrogen bubble react 60 minutes.Then about 5n is added to work as
Methanol is measured, half an hour is reacted, takes out reaction solution, cleaned with DMF, MEOH；
B. toward second amino acid (being also 2n equivalents) in addition sequence in reactor, 2n equivalents HBTU (1- hydroxyls, benzene
And three chlorazol tetramethyl hexafluorophosphates) and DIEA, nitrogen bubble reaction half an hour, wash liquid off, ninhydrin detection, then
Blocked with pyridine and acetic anhydride.Finally clean, add appropriate liquid of raising one's hat and remove Fmoc (9-fluorenylmethyloxycarbonyl) protection group, wash
Only, ninhydrin detects；
C. sequentially add amino acid different in sequence according to step b mode and carry out various modifications；
D. remove, pour into flask from reaction column after resin is dried up with nitrogen, then toward in flask plus a certain amount of (cutting
Liquid and resin are cut about with 10ml/ grams of ratio) cutting liquid (form is 95%TFA, 2% dithioglycol, 2% triisopropyl
Silane, 1% water), concussion, filter resin；
Filtrate is obtained, a large amount of ether are then added into filtrate, crude product is separated out, is then centrifuged for, cleaning can obtain sequence
The crude product of row；
Peptide purification：Rp-hplc method purifies crude product, and polypeptide is connected on column packing by hydrophobic effect, reduce gradually from
Sub- intensity is eluted.Quantified using determined by ultraviolet spectrophotometry polypeptide UV absorption.
2.HIP-20 wear film and cellular localization detect
Human neuroblastomacells SH-SY5Y is respectively adopted and Human cervical cancer cell lines HeLa is tested.Take pair
The cell in number growth period, is planted on the cover glass in 24 orifice plates, per about 8000-10000, hole cell.With 10% tire ox blood
Clearly, DMEM in high glucose medium culture, and 20 μm of ol/L polypeptide is added, maintain 48 hours.Supernatant discarding, add 4% poly first
The μ l/ holes of aldehyde 300, room temperature fix cell 20 minutes, discard paraformaldehyde, 1 × PBS twice, 5 minutes every time.Add DAPI
The μ l/ holes of solution 300, room temperature dye nucleus 5 minutes, 1 × PBS is fully washed 5 times, every time 5 minutes.Then with the μ of after birth dyestuff 2
The μ l/ holes of mol/L concentration 200, room temperature dye cell membrane 5-10 minutes, contaminate and concussion is kept in membrane process, subsequent 1 × PBS fully washs 5
It is secondary, 5 minutes every time.Pure glycerin mounting, cover glass is fixed on slide.Using laser confocal microscope detection with glimmering
The positioning of the polypeptide of light group in the cell, takes pictures and preserves.
As a result as shown in figure 1, the polypeptide can be efficiently entering tumour cell after cell culture system is added 48 hours,
And show extremely strong karyon positioning.And control peptide is only capable of part and enters cytoplasm, very small amount is distributed in nucleus.It can be seen that the polypeptide
Tumour cell can be efficiently entering and be positioned in karyon.
3.MTT colorimetrically analysings detect inhibitory action of the HIP-20 to growth of tumour cell
Respectively MTT cell viability colorimetric tests are carried out using human neuroblastomacells SH-SY5Y.In 96 hole cells
In culture plate, 5000 cells are planted per hole, each sample sets 8 multiple holes.After 12 hours, HIP-20 and control peptide are added.
0.05,0.5,5,50 μm of ol/L polypeptides detection IC50 is given first.Secondly drug concentration is corresponded to according to IC50, given according to IC50
Polypeptide and its control peptide concentration are respectively 5,10,20,40 μm of ol/L；Finally give 20 μm of ol/L certain concentrations polypeptides and control
It is 12,24,48,72 hours that peptide action time, which is respectively,.
After reaching the nominal time, supernatant discarding, with 1 × PBS sample well 3 times, every time 5 minutes.Again into sample well
Add 100 μ l dimethyl sulfoxide (DMSO)s (DMSO) solution.Culture plate is statically placed in 37 DEG C, 10 minutes.Sample in hole is gently mixed after taking-up
Product.570nm absorbances are detected with ELIASA.Data are collected, calculates and counts.
As a result as shown in Figures 2 and 3, compared with compareing polypeptide, the vigor of the tumour cell of HIP-20 polypeptides processing significantly drops
It is low, and the effect is in time and dose dependent, illustrates that the novel polypeptide can effectively reduce the cell viability of tumour cell；It is imitated
Fruit is more obvious in 20 μm of ol/L concentration 48 hours.And control peptide does not show significantly to suppress growth effects.
4. soft-fractrue rock mass experiment detection HIP-20 is to the inhibitory action of proliferative activity o f tumor
Take the logarithm SH-SY5Y the and HeLa cells in growth period, blow and beat with 0.25% Trypsin Induced and gently, be allowed into
To be unicellular, make viable count.Six orifice plates are per the control of hole cell number at 1000.Prepare 1.2% He respectively with distilled water
The low melting point agar liquid glucose of 0.7% two concentration, after autoclaving, maintaining in 40 DEG C to solidify.By polypeptide according to 20 μ
Mol/L concentration is added in culture medium, then by 1:1 ratio makes 1.2% agarose and 2 × 1640 culture mediums (contain 2 × antibiotic
With 20% calf serum) mixing after, take 3ml mixed liquors inject six orifice plates, cooled and solidified, CO can be put as bottom-layer agar2Incubator
In it is standby.By 1:1 ratio allows 0.7% agarose and 2 × DMEM culture mediums mutually to be mixed in sterile test tube and prepare 2ml upper stratas later
Glue, then 0.2ml cell suspension is added into pipe, fully mix, inject in bottom plate, form double agar layers.Treat upper strata fine jade
After fat solidification, 37 DEG C, 5%CO are inserted2Cultivated 21-28 days in incubator, treat that it forms cell colony.Six orifice plates completed to culture
Middle addition 0.5%MTT solution, 4 DEG C of dyeing 2-3 hours, take out observation photograph.Count cell colony and form number.
As a result as shown in Figures 4 and 5, compared with control group polypeptide, the tumour of 20 μm of ol/L of concentration HIP-20 polypeptides processing
Clone's Colony forming of cell significantly reduces, and illustrates that the novel polypeptide can effectively suppress the multiplication capacity of tumour cell.
Influences of the 5.Transwell experiments detection HIP-20 to tumor cell migration activity
Corning company's T ranswell cells (article No. is placed in 24 well culture plates：3422), add and contain to bottom
The complete medium of 15% hyclone.And the control peptide and HIP-20 of 20 μm of ol/L concentration are added into culture medium.With without blood
Clear culture medium prepares single cell suspension, after counting, with the concentration of 8000-20000 cell in 200 μ l serum free mediums to
200 μ l cell suspensions are added in Transwell upper chambers.And upward indoor addition and the polypeptide of lower room same concentrations.5%CO2、37
DEG C culture 24 hours.Taking-up cell, which is put into 4% paraformaldehyde, fixes 20 minutes, places into 0.5% violet staining liquid, room
Temperature dyeing 2 hours.The cell that perforated membrane is not passed through in upper chamber is gently removed with cotton swab, perforated membrane is carried out under inverted microscope
Photograph counts.
As a result as shown in Figures 6 and 7, compared with control group polypeptide, the migration number of the tumour cell of HIP-20 processing is obvious
Reduce, illustrate that the novel polypeptide can effectively suppress the transfer ability of tumour cell.
The detection of suppression of the 6.HIP-20 to tumour cell angiogenic activity
Tumour cell angiogenic activity, can be by detecting SH-SY5Y and HeLa cells in extracellular matrix glue
Growth and vascularization state are detected；Embodiment is as follows, SH-SY5Y and HeLa cells are with 70-80% density
12 orifice plates are plated on, 1ml culture mediums are added per hole, add the polypeptide and control peptide of 20 μm of ol/L concentration；In 37 DEG C, 5%CO2
Environment culture 48 hours, collect culture hole in supernatant, mark freeze it is standby at -80 DEG C；Matrigels are taken out from -20 DEG C,
Rewarming is to melting state in ice-water bath.48 porocyte culture plates are taken, 100 μ l matrigels are added per hole to bottom hole, it is horizontal positioned
In 37 DEG C of incubators 30 minutes, treat that matrigel solidifies；HUVEC single cell suspensions are prepared, after counting, are added to 48 orifice plates per hole
8000-10000 cell, add the control polypeptide and HIP-20 treatment group SH-SY5Y and HeLa cells and supernatants of collection
100μl；In 37 DEG C, 5%CO2Environment culture 6-8 hours, dynamic realtime observation HUVEC tubules form shape under inverted microscope
State, take pictures in good time.
As a result as shown in FIG. 8 and 9, compared with control peptide, 20 μm of ol/L of concentration polypeptide can significantly inhibit tumour cell blood
Pipe generates.
7.HIP-20 suppresses the mechanism of action of tumour
Detected using RNA pull-down and RIP to inquire into the mechanism of action that HIP-20 suppresses tumour.
Depression effect of the polypeptide to LncRNA and hnRNPU protein-interactings is detected using HeLa.Into 10cm culture dishes
The cell of culture adds the polypeptide (0,5,10,20 μm of ol/L) of various concentrations, while separately sets 20 μm of ol/L control polypeptide groups, processing
48 hours；0.25% Trypsin Induced, cell is collected, 1 × PBS washings, removes supernatant；Fully split with RIPA lysates 1ml
Cell mass is solved, lysate is divided into two equal portions, takes 50 μ l to be frozen as Input groups in -80 DEG C, 450 μ l are as RIP for remainder
Group, add 30 μ l and mix magnetic bead and 1 μ g LncRNA probes, another group of addition hnRNPU protein antibodies and sepharose 4B in advance, put
Mixing overnight is rotated with 10rpm in 4 DEG C of refrigerators；The test tube mixed overnight is taken out, 3000rpm is centrifuged 1 minute, abandons supernatant, is added
Pearl is resuspended in 1ml1 × PBS, and 3000rpm is centrifuged 1 minute, carefully sucks supernatant, 4-5 times repeatedly, by the part of uncombined pearl
Cleaning discards.After last time is washed, supernatant is carefully removed, 40 μ l PBS is added and pearl is resuspended；Add 10 5 × SDS of μ l
PAGE loading buffer, 95 DEG C of water-baths 10 minutes after mixing, dissociate the albumen and RNA on pearl；By the nucleic acid of elution
Composition specific primer enters performing PCR amplification.
12%SDS-PAGE glue is prepared, cuts hnRNPU albumen (120KDa) band, transferring film after electrophoresis according to molecular weight
Closing, corresponding antibodies are incubated post-exposure.According to the polypeptide of the light and shade interpretation various concentrations of band to LncRNA and hnRNPU albumen
The inhibition of interaction.1.5% Ago-Gel is prepared, goes the PCR primer of equal volume to carry out electroresis appraisal, according to electricity
Band brightness of swimming carries out sxemiquantitative comparison.
As a result as shown in FIG. 10 and 11, detected using western blot, Input groups are shown per histone applied sample amount phase
Deng, RNA pull-down groups are shown with the raising of HOP-20 concentration, with LncRNA probes combine hnRNPU albumen gradually subtract
It is few, illustrate that HIP-20 polypeptides can suppress be combineding with each other for LncRNA and hnRNPU albumen.
The foregoing is only presently preferred embodiments of the present invention, be not intended to limit the invention, it is all the present invention spirit and
Within principle, any modification, equivalent substitution and improvements made etc., it should be included in the scope of the protection.
Sequence table
<110>Wuhan Union Hospital
<120>It is a kind of can antagonism hnRNPU protein rna binding activity polypeptide HIP-20 and its application
<130> 1
<160> 3
<170> PatentIn version 3.5
<210> 1
<211> 20
<212> PRT
<213>Artificial sequence
<400> 1
Asn Met Arg Gly Gly Asn Phe Arg Gly Gly Ala Pro Gly Asn Arg Gly
1 5 10 15
Gly Tyr Asn Lys
20
<210> 2
<211> 11
<212> PRT
<213>Artificial sequence
<400> 2
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg
1 5 10
<210> 3
<211> 31
<212> PRT
<213>Artificial sequence
<400> 3
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Asn Met Arg Gly Gly
1 5 10 15
Asn Phe Arg Gly Gly Ala Pro Gly Asn Arg Gly Gly Tyr Asn Lys
20 25 30
Claims (6)
1. it is a kind of can antagonism hnRNPU protein rna binding activity polypeptide, it is characterised in that amino acid sequence such as SEQ ID NO:
Shown in 1.
2. described in claim 1 can antagonism hnRNPU protein rna binding activity polypeptide in antineoplastic is prepared should
With.
3. a kind of antineoplastic polypeptide, it is characterised in that including tumor cytotoxicity domain and wear spanning domain, the tumour is thin
Born of the same parents kill the amino acid sequence such as SEQ ID NO of domain:Shown in 1.
4. antineoplastic polypeptide according to claim 3, it is characterised in that the amino acid sequence for wearing spanning domain is such as
SEQ ID NO:Shown in 2.
5. the antineoplastic polypeptide according to claim 3 or 4, it is characterised in that the spanning domain of wearing is connected to described swell
The N-terminal of cytotoxic effect domain.
6. application of the antineoplastic polypeptide any one of claim 3-5 in antineoplastic is prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710802024.2A CN107417772B (en) | 2017-09-07 | 2017-09-07 | Polypeptide HIP-20 capable of antagonizing RNA binding activity of hnRNPU protein and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710802024.2A CN107417772B (en) | 2017-09-07 | 2017-09-07 | Polypeptide HIP-20 capable of antagonizing RNA binding activity of hnRNPU protein and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107417772A true CN107417772A (en) | 2017-12-01 |
| CN107417772B CN107417772B (en) | 2020-03-27 |
Family
ID=60432874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710802024.2A Active CN107417772B (en) | 2017-09-07 | 2017-09-07 | Polypeptide HIP-20 capable of antagonizing RNA binding activity of hnRNPU protein and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107417772B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108864311A (en) * | 2018-08-03 | 2018-11-23 | 中国人民解放军第四军医大学 | A kind of inhibition MD2 and the protein bound small peptide of CIRP and its application |
| CN114605501A (en) * | 2022-04-07 | 2022-06-10 | 华中科技大学同济医学院附属协和医院 | Polypeptide FIP-21 capable of antagonizing RNA binding activity of FUS protein and application thereof |
| CN115850388A (en) * | 2022-11-29 | 2023-03-28 | 深圳市人民医院 | lncRNA coded anti-cancer peptide AC115619-22AA and application |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1325862A (en) * | 2000-05-31 | 2001-12-12 | 上海博德基因开发有限公司 | Polypeptide-eucaryotic RNA binding domain RNP-1-9 and polynucleotide for coding it |
| WO2002076389A2 (en) * | 2001-03-21 | 2002-10-03 | The Trustees Of Boston University | Compositions and methods to prevent metastasis from primary malignancies |
| CN1771335A (en) * | 2003-02-13 | 2006-05-10 | 加州大学评议会 | Methods and compositions for detection and analysis of polynucleotide-binding protein interactions using light harvesting multichromophores |
| CN104388428A (en) * | 2014-10-22 | 2015-03-04 | 中国医科大学附属第一医院 | Double-chain siRNA for interfering hnRNPA2/B1 gene expression and application thereof |
-
2017
- 2017-09-07 CN CN201710802024.2A patent/CN107417772B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1325862A (en) * | 2000-05-31 | 2001-12-12 | 上海博德基因开发有限公司 | Polypeptide-eucaryotic RNA binding domain RNP-1-9 and polynucleotide for coding it |
| WO2002076389A2 (en) * | 2001-03-21 | 2002-10-03 | The Trustees Of Boston University | Compositions and methods to prevent metastasis from primary malignancies |
| CN1771335A (en) * | 2003-02-13 | 2006-05-10 | 加州大学评议会 | Methods and compositions for detection and analysis of polynucleotide-binding protein interactions using light harvesting multichromophores |
| CN104388428A (en) * | 2014-10-22 | 2015-03-04 | 中国医科大学附属第一医院 | Double-chain siRNA for interfering hnRNPA2/B1 gene expression and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| BRAMSWIG NC等: "heterogeneous nuclear ribonucleoprotein U isoform a [Homo sapiens]", 《GENBANK》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108864311A (en) * | 2018-08-03 | 2018-11-23 | 中国人民解放军第四军医大学 | A kind of inhibition MD2 and the protein bound small peptide of CIRP and its application |
| CN114605501A (en) * | 2022-04-07 | 2022-06-10 | 华中科技大学同济医学院附属协和医院 | Polypeptide FIP-21 capable of antagonizing RNA binding activity of FUS protein and application thereof |
| CN114605501B (en) * | 2022-04-07 | 2023-06-30 | 华中科技大学同济医学院附属协和医院 | Polypeptide FIP-21 capable of antagonizing FUS protein RNA binding activity and application thereof |
| CN115850388A (en) * | 2022-11-29 | 2023-03-28 | 深圳市人民医院 | lncRNA coded anti-cancer peptide AC115619-22AA and application |
| CN115850388B (en) * | 2022-11-29 | 2023-09-26 | 深圳市人民医院 | lncRNA encoded anticancer peptide AC115619-22AA and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107417772B (en) | 2020-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220185893A1 (en) | Genetically engineered dual-targeting chimeric antigen receptor and use thereof | |
| CN113498417B (en) | Polypeptide, preparation method and application thereof | |
| CN105567641B (en) | A kind of preparation method and applications carrying anti-tumor protein targeting exosome | |
| CN103201386A (en) | Skin permeating and cell entering (SPACE) peptides and methods of use thereof | |
| BR112021003410A2 (en) | anti-bcma single domain antibodies, gene group of said antibodies, polypeptide, expression vector, host cell, chimeric antigen receptor, t cell modified by the same, pharmaceutical composition and uses of said antibodies | |
| WO2018053885A1 (en) | Preparation method for and use of enhanced slit2 car-t cell and car-nk cell | |
| CN107417772A (en) | It is a kind of can antagonism hnRNPU protein rna binding activity polypeptide HIP 20 and its application | |
| CN105368859A (en) | Chimeric antigen receptor hCD87-CAR, lentivirus carrying hCD87-CAR gene structure, plasmid and application of chimeric antigen receptor hCD87-CAR | |
| WO2022120942A1 (en) | Cll1-targeting chimeric antigen receptor and application thereof | |
| CN110054701B (en) | Anti-tumor target drug delivery system based on mesenchymal stem cells and application thereof | |
| CN109678987A (en) | A kind of hydrogen sulfide releasing agent HA-ADT, preparation method and application | |
| Yamaguchi et al. | Effects of Clostridium perfringens enterotoxin via claudin-4 on normal human pancreatic duct epithelial cells and cancer cells | |
| CN112955460B (en) | Scyreproxcin as antibacterial peptide of scylla paramamosain and application thereof | |
| CN107446022B (en) | Polypeptide PIP-14 capable of antagonizing RNA binding activity of PARP1 protein and application thereof | |
| CN101643511B (en) | Fusion protein for inhibiting telomerase activity, preparation and application thereof | |
| CN106699850A (en) | RBBP4 targeting polypeptide and anti-tumor polypeptide, and applications thereof | |
| CN103626846A (en) | Ligand polypeptide specifically combined with MDSCs (Myeloid-Derived Suppressor Cells) and drug delivery system | |
| CN107446023B (en) | Polypeptide HIP-13 capable of antagonizing RNA binding activity of HuR protein and application thereof | |
| CN107022004B (en) | Polypeptide targeting tumor cells and application thereof | |
| CN110526976A (en) | It is a kind of to target the single-chain antibody of PSMA, Chimeric antigen receptor T cell and its preparation method and application | |
| CN107602670A (en) | It is a kind of can antagonism EWSR1 protein rna binding activity polypeptide EIP 22 and its application | |
| CN111956795A (en) | Application of chimeric antigen receptor combined anti-tumor drug taking CD99 as target | |
| CN106831956B (en) | A kind of antineoplastic polypeptide MUDP-21 and its application | |
| CN107446024B (en) | Polypeptide DIP-13 capable of antagonizing RNA binding activity of DDX3 protein and application thereof | |
| CN110129272A (en) | Stablize the PK-15 cell strain for expressing MAP3K8 albumen and its building and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |